RMTG expands ISSCA peptide certification, links training to Cellgenic products
The OTC-listed company says the credential is company-issued and not a governmental or board-specialty accreditation.
TR
By Tom Reyes · Markets Editor
Oct 1 07:02 ETSource: FinanzNachrichten.de
The wire
- 01Regenerative Medical Technology Group launched Peptide Certification 2.0 through its ISSCA division, adding modules and two physician reference guides, with the stated aim of connecting training to subsidiary Cellgenic's peptide product portfolio.
- 02CEO David Christensen describes the model as building physician relationships through education, then selling products and services 'where legally permitted', a pattern clinicians evaluating peptide credentials should recognize.
- 03The company states the program is not a substitute for medical licensure, product labeling or regulatory authorization; no enrollment numbers, pricing or revenue figures were disclosed.
From the source
Read at finanznachrichten.deRegenerative Medical Technology Group: RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides
The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model.
